Latest Pharma-VC Experiment: Arteaus Gets $18M For Migraine Drug Licensed From Lilly
This article was originally published in The Pink Sheet Daily
Executive Summary
Atlas Venture and OrbiMed Advisors have launched a virtual company to support development of a single asset, which Lilly can buy back after a Phase II trial.
You may also be interested in...
Lilly’s Venture Strategy Matures As PoC Data Catalysts Approach
As part of a new R&D investment approach, Eli Lilly has partnered with TVM Capital and HealthCare Ventures, which have raised $250 million and funded the start of eight single-molecule companies. Corporate Business Development VP Darren Carroll discussed how the company’s venture initiative has evolved during Elsevier’s Pharmaceutical Strategic Alliance conference Sept. 25.
With Partner Lilly, TVM Capital Gets A Canadian Makeover
One of two venture firms signed up to run an Eli Lilly “mirror portfolio” of single-asset companies, venerable TVM Capital has made significant changes to get its new model off the ground.
Financings Of The Fortnight: Life Science Venture Funding Not Necessarily On The Decline
Plus news on recent financings by Foundation Medicine, Ultragenyx, Labrys Biologics, Solstice Biologics and Sarepta Therapeutics.